EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study

Aliisa Auvinen iD, Panu Aaltonen, Harri Mustonen, Caj Haglund, Pauli Puolakkainen, Hanna Seppänen

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01662-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Gastric Cancer, 2025. Verfasst von Aliisa Auvinen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Translational Cancer Medicine Research Program, iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, Universi…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Helsinki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The renin–angiotensin system (RAS) has been increasingly recognized to be associated with carcinogenesis and cancer progression. There is extensive preclinical evidence suggesting the benefits of RAS-inhibiting drugs, such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs), in preventing the progression of gastric cancer (GC). However, clinical evidence supporting the positive effects of ARBs and ACEIs on GC prognosis is currently limited. The purpose of this study is to investigate their effects in a Finnish cohort.

Methods

This is a retrospective national cohort study, where cancer patient registry data were linked to prescription purchase records for ARBs and ACEIs. The effect of ARB/ACEI in the post-diagnostic period on overall mortality was assessed using Cox regression analysis. Disease-specific mortality associations were evaluated with the Fine and Gray model.

Results

We included 2246 histologically confirmed GC patients diagnosed between 2011 and 2016. Follow-up continued until the end of 2023. In the main analysis, a protective effect of ARB use was associated with a significant reduction in overall mortality (adjusted hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69–0.94, p = 0.007). Furthermore, the effect was greater for those with higher ARB dosage. A similar finding was not observed with ACEI use. For disease-specific survival, both ARB and ACEI use had a significant protective effect (adjusted HR 0.75, 95% CI 0.62–0.90 p = 0.002 and adjusted HR 0.76, 95% CI 0.63–0.93, P = 0.007, respectively).

Conclusions

Our study adds to the evidence that ARB use might have a beneficial impact on survival among GC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsStomach NeoplasmsHumansMaleFemaleFinlandRetrospective StudiesAgedMiddle AgedPrognosisSurvival RateAged, 80 and overCohort StudiesRegistriesRenin-Angiotensin System

Stichwörter der Autor:innen

Angiotensin receptor blockerAngiotensin-converting enzyme inhibitorEpidemiologyGastric cancerSurvival

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Surgery, Translational Cancer Medicine Research Program, iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, PL…

ORCID-Profile: Aliisa Auvinen

Förderung

  • University of Helsinki

Zitieren

APA

Auvinen, A., Aaltonen, P., Mustonen, H., Haglund, C., Puolakkainen, P., & Seppänen, H. (2025). Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study. Gastric Cancer. https://doi.org/10.1007/s10120-025-01662-2

Vancouver

Auvinen A, Aaltonen P, Mustonen H, Haglund C, Puolakkainen P, Seppänen H. Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study. Gastric Cancer. 2025. doi:10.1007/s10120-025-01662-2

BibTeX
@article{Auvinen2025,
  author = {Auvinen, Aliisa and Aaltonen, Panu and Mustonen, Harri and Haglund, Caj and Puolakkainen, Pauli and Seppänen, Hanna},
  title = {Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01662-2}
}
Kostenlos starten →